Donald L Trump

US Patent:

6559139, May 6, 2003

Filed:

Apr 6, 2000

Appl. No.:

09/544724

Inventors:

Candace S. Johnson - Pittsburgh PA
Donald L. Trump - Pittsburgh PA

Assignee:

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61K 3159

US Classification:

514168, 514170, 514167, 514449, 514110, 514653

Abstract:

This invention relates to combination chemotherapy, particularly involving vitamin D or a derivative thereof. In one aspect, the invention provides a method of killing a cell by first administering to the cell vitamin D (or a derivative) and subsequently administering to the cell a cytotoxic agent. Where this strategy is applied to an intact tumor, the present invention provides a method of retarding the growth of the tumor by first administering vitamin D (or a derivative) to the tumor and subsequently administering the cytotoxic agent. A further aspect of the invention concerns a method of treating prostate cancer within a patient by co-administration of vitamin D (or a derivative) and a glucocorticoid to the patient. In yet a further aspect, the invention provides an improved method of treating a patient with vitamin-D involving the adjunctive administration of zoledronate.

US Patent:

6974791, Dec 13, 2005

Filed:

Mar 16, 2001

Appl. No.:

09/810700

Inventors:

Michael K. Wong - Wexford PA, US
Ruth A. Modzelewski - Glenshaw PA, US
Charles Komen Brown - Chicago IL, US
Candace S. Johnson - Pittsburgh PA, US
Donald L. Trump - Pittsburgh PA, US

Assignee:

The University of Pittsburgh - Pittsburgh PA

International Classification:

A61K038/00
A61K038/08
C07K007/00

US Classification:

514 2, 514 15, 530328

Abstract:

Peptide motifs which define specificity of tumor-derived endothelial cells. These peptides possess a charge motif of positive-positive-hydrophobic which is important in determining the specificity of binding to tumor-derived endothelium. The specific molecular peptide motifs will facilitate diverse therapeutic and diagnostic applications including: anti-angiogenic therapies to be used in alone or in conjunction with standard therapies; imaging tools for both detection of very small metastasis that are undetectable by current techniques; for monitoring tumor response; for targeting and directing chemotherapy drugs to the tumor; for treatment of chronic inflammatory diseases such as rheumatoid arthritis and psoriasis, for treating some forms of blindness; as well as other diagnostic and therapeutic applications.

US Patent:

20030176403, Sep 18, 2003

Filed:

Mar 17, 2003

Appl. No.:

10/390234

Inventors:

Candace Johnson - Pittsburgh PA, US
Donald Trump - Pittsburgh PA, US

Assignee:

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61K031/675

US Classification:

514/168000, 514/094000

Abstract:

The invention provides a method of treating a patient with vitamin-D or a derivative thereof involving the adjunctive administration of zoledronate.

US Patent:

20030216359, Nov 20, 2003

Filed:

May 5, 2003

Appl. No.:

10/429840

Inventors:

Candace Johnson - Pittsburgh PA, US
Donald Trump - Pittsburgh PA, US

Assignee:

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61K033/24
A61K031/675
A61K031/704
A61K031/66
A61K031/56
A61K031/28

US Classification:

514/168000, 514/034000, 514/089000, 514/102000, 514/170000, 514/492000, 424/649000

Abstract:

This invention relates to combination chemotherapy, particularly involving vitamin D or a derivative thereof. In one aspect, the invention provides a method of killing a cell by first administering to the cell vitamin D (or a derivative) and subsequently administering to the cell a cytotoxic agent. Where this strategy is applied to an intact tumor, the present invention provides a method of retarding the growth of the tumor by first administering vitamin D (or a derivative) to the tumor and subsequently administering the cytotoxic agent. A further aspect of the invention concerns a method of treating prostate cancer within a patient by co-administration of vitamin D (or a derivative) and a glucocorticoid to the patient. In yet a further aspect, the invention provides an improved method of treating a patient with vitamin-D involving the adjunctive administration of zoledronate.

US Patent:

20050234009, Oct 20, 2005

Filed:

Mar 29, 2005

Appl. No.:

11/093123

Inventors:

Candace Johnson - Amherst NY, US
Donald Trump - Buffalo NY, US

International Classification:

A61K031/7076
A61K031/7072
A61K031/59

US Classification:

514045000, 514049000, 514167000

Abstract:

The present invention relates to a method of inhibiting solid tumor cell or leukemia cell proliferation by first administering to a solid tumor cell or leukemia cell either vitamin D or a derivative thereof and subsequently administering at least one anti-metabolic nucleoside analog to the solid tumor cell or the leukemia cell. Also disclosed is a method of treating a cancerous condition. Methods of down regulating a p-AKt survival signaling pathway and modulating activity of a pro-apoptotic caspases is also disclosed.

US Patent:

20060148752, Jul 6, 2006

Filed:

Feb 28, 2006

Appl. No.:

11/363667

Inventors:

Candace Johnson - Amherst NY, US
Donald Trump - Buffalo NY, US

International Classification:

A61K 31/7072
A61K 31/7076
A61K 31/59

US Classification:

514045000, 514049000, 514167000

Abstract:

The present invention relates to a method of inhibiting solid tumor cell or leukemia cell proliferation by first administering to a solid tumor cell or leukemia cell either vitamin D or a derivative thereof and subsequently administering at least one anti-metabolic nucleoside analog to the solid tumor cell or the leukemia cell. Also disclosed is a method of treating a cancerous condition. Methods of down regulating a p-AKt survival signaling pathway and modulating activity of a pro-apoptotic caspases is also disclosed.

US Patent:

20070207488, Sep 6, 2007

Filed:

Jan 31, 2007

Appl. No.:

11/700462

Inventors:

Donald Trump - Pittsburgh PA, US
Josephia Muindi - Willamsville NY, US
Lionel Coignet - East Amherst NY, US
Candace Johnson - Amherst NY, US

International Classification:

C12Q 1/68
C12P 19/34

US Classification:

435006000, 435091200

Abstract:

A method is provided for identifying an individual as having altered vitamin D metabolism comprising analyzing a biological sample from the individual for the presence of CYP24 SNPs and/or aberrantly spliced CYP24 mRNA. The presence of the SNPs and/or the aberrantly spliced CYP24 mRNA indicates that the individual has altered vitamin D metabolism. Also provided are methods for customizing dosages of biologically active vitamin D compounds for individuals who are determined to have altered vitamin D metabolism.

US Patent:

20080003304, Jan 3, 2008

Filed:

Jan 29, 2007

Appl. No.:

11/668330

Inventors:

Candace Johnson - Buffalo NY, US
Donald Trump - Pittsburgh PA, US

Assignee:

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61K 31/59
A61K 33/24
A61P 35/00

US Classification:

424649000, 514167000

Abstract:

This invention relates to combination chemotherapy, particularly involving vitamin D or a derivative thereof hi one aspect, the invention provides a method of killing a cell by first administering to the cell vitamin D (or a derivative) and subsequently administering to the cell a cytotoxic agent. Where this strategy is applied to an intact tumor, the present invention provides a method of retarding the growth of the tumor by first administering vitamin D (or a derivative) to the tumor and subsequently administering the cytotoxic agent. A further aspect of the invention concerns a method of treating prostate cancer within a patient by co-administration of vitamin D (or a derivative) and a glucocorticoid to the patient. In yet a further aspect, the invention provides an improved method of treating a patient with vitamin-D involving the adjunctive administration of zoledronate.